BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28158397)

  • 1. Profoundly Expanded T-cell Clones in the Inflamed and Uninflamed Intestine of Patients With Crohn's Disease.
    Doorenspleet ME; Westera L; Peters CP; Hakvoort TBM; Esveldt RE; Vogels E; van Kampen AHC; Baas F; Buskens C; Bemelman WA; D'Haens G; Ponsioen CY; Te Velde AA; de Vries N; van den Brink GR
    J Crohns Colitis; 2017 Jul; 11(7):831-839. PubMed ID: 28158397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of T-cell Receptor Repertoire in Inflamed Tissues of Patients with Crohn's Disease Through Deep Sequencing.
    Chapman CG; Yamaguchi R; Tamura K; Weidner J; Imoto S; Kwon J; Fang H; Yew PY; Marino SR; Miyano S; Nakamura Y; Kiyotani K
    Inflamm Bowel Dis; 2016 Jun; 22(6):1275-85. PubMed ID: 27135481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
    Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cell Repertoire Homogeneity and Blood-Gut Overlap in Patients With Inflammatory Bowel Disease.
    Williams KG; Kongala R; Shows DM; Konecny AJ; Hindmarch DC; Clarke AS; Lord JD
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):119-130. PubMed ID: 37714427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon.
    Verstockt B; Verstockt S; Abdu Rahiman S; Ke BJ; Arnauts K; Cleynen I; Sabino J; Ferrante M; Matteoli G; Vermeire S
    J Crohns Colitis; 2021 Mar; 15(3):485-498. PubMed ID: 32915959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
    Dige A; Magnusson MK; Öhman L; Hvas CL; Kelsen J; Wick MJ; Agnholt J
    Scand J Gastroenterol; 2016; 51(6):692-9. PubMed ID: 26784676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence.
    Allez M; Auzolle C; Ngollo M; Bottois H; Chardiny V; Corraliza AM; Salas A; Perez K; Stefanescu C; Nancey S; Buisson A; Pariente B; Fumery M; Sokol H; Tréton X; Barnich N; Seksik P; Le Bourhis L;
    Gut; 2019 Nov; 68(11):1961-1970. PubMed ID: 30792246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
    World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mucosal healing in different intestinal segments in patients receiving infliximab treatment for small bowel Crohn's disease].
    Zhu ZH; Qiu C; Zhang M; Chen Z; Xiang C; Wang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):44-48. PubMed ID: 28109097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
    Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced diversity of intestinal T-cell receptor repertoire in patients with Crohn's disease.
    Hong SN; Park JY; Yang SY; Lee C; Kim YH; Joung JG
    Front Cell Infect Microbiol; 2022; 12():932373. PubMed ID: 36034703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
    ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
    Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.